# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001477932-22-002686
Filing Date
2022-04-28
Accepted
2022-04-28 16:04:59
Documents
5
Period of Report
2022-04-28

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | vnrx_def14a.htm | DEF 14A | 769540
2 |  | vnrx_def14aimg1.jpg | GRAPHIC | 140928
3 |  | vnrx_def14aimg2.jpg | GRAPHIC | 177937
4 |  | vnrx_def14aimg3.jpg | GRAPHIC | 164014
5 |  | vnrx_def14aimg4.jpg | GRAPHIC | 130722
| Complete submission text file | 0001477932-22-002686.txt |  | 1616177

Mailing Address 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738
Business Address 13215 BEE CAVE PARKWAY, SUITE 125, GALLERIA OAKS B AUSTIN TX 78738 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36833 | Film No.: 22866447
SIC: 2835 In Vitro & In Vivo Diagnostic Substances